Larson Financial Group LLC Sells 654 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Larson Financial Group LLC lowered its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 21.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,351 shares of the biopharmaceutical company’s stock after selling 654 shares during the period. Larson Financial Group LLC’s holdings in Catalyst Pharmaceuticals were worth $49,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in CPRX. abrdn plc bought a new position in shares of Catalyst Pharmaceuticals during the fourth quarter valued at about $10,115,000. Raymond James Financial Inc. purchased a new stake in Catalyst Pharmaceuticals during the 4th quarter valued at about $6,887,000. Jane Street Group LLC grew its position in Catalyst Pharmaceuticals by 245.4% during the 3rd quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after acquiring an additional 285,564 shares during the last quarter. Walleye Capital LLC purchased a new position in Catalyst Pharmaceuticals in the 3rd quarter worth approximately $4,936,000. Finally, Pacer Advisors Inc. lifted its position in Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock valued at $61,681,000 after purchasing an additional 151,495 shares during the last quarter. Hedge funds and other institutional investors own 79.22% of the company’s stock.

Analyst Upgrades and Downgrades

CPRX has been the topic of several analyst reports. Bank of America reaffirmed a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 28th. Robert W. Baird increased their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, March 3rd. Stephens reissued an “overweight” rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $32.50.

Insider Activity

In other news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Brian Elsbernd sold 62,975 shares of the business’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by company insiders.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $21.20 on Thursday. Catalyst Pharmaceuticals, Inc. has a fifty-two week low of $14.47 and a fifty-two week high of $24.64. The stock has a market cap of $2.57 billion, a price-to-earnings ratio of 17.97, a PEG ratio of 3.31 and a beta of 0.84. The stock’s 50 day simple moving average is $22.27 and its two-hundred day simple moving average is $21.52.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.